Drugs / OPM cells
OPM cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06621303 | Oct 2024 → Sep 2025 overdue | ulcer of lower limbs | Shanghai East Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPM cells | “Preliminary animal experiments and European clinical studies have shown that injecting OPM cells into the muscle around diabetic ulcers increases the paracrine of proteins...” NCT06621303 ↗ |
| Known as | Autonomous Regulatory Monocytes | “Autonomous Regulatory Monocytes (OPM Cells) for the Treatment of Diabetic Foot in a Single-arm Open-label Clinical Study” NCT06621303 ↗ |
| Known as | autoregulatory monocytes | “has developed autoregulatory monocytes (OPM cells).” NCT06621303 ↗ |
| Route | Intramuscular | “The OPM cells must be injected into the muscle around the ulcer within 6 hours after leaving the laboratory.” NCT06621303 ↗ |